研究单位：[1]The First Affiliated Hospital of Fujian Medical University, Fuzhou 350212, China[2]Shenzhen Salubris Pharmaceuticals Co., Ltd.[3]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China[4]Xuancheng People''s Hospital,Xuancheng,Anhui,China[5]Aerospace Central Hospital,Beijing,Beijing,China[6]China-Japan Friendship Hospital,Beijing,Beijing,China[7]Chongqing University Affiliated Three Gorges Hospital,Chongqing,Chongqing,China[8]The First Affiliated Hospital of Fujian Medical University,Fuzhou,Fujian,China[9]Gansu Provincial People''s Hospital,Lanzhou,Gansu,China[10]Shunde Hospital of Southern Medical University,Foshan,Guangdong,China[11]Guangdong Medical University Affiliated Hospital,Zhanjiang,Guangdong,China[12]Nanning First People''s Hospital,Nanning,Guangxi,China[13]Hebei Provincial People''s Hospital,Shijiazhuang,Hebei,China[14]Shijiazhuang People''s Hospital,Shijiazhuang,Hebei,China[15]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China[16]The Third Hospital of Hebei Medical University,Shijiazhuang,Hebei,China[17]Daqing People''s Hospital,Daqing,Heilongjiang,China[18]Kaifeng Traditional Chinese Medicine Hospital,Kaifeng,Henan,China[19]Chinese Medicine Dongfeng General Hospital,Shiyan,Hubei,China[20]Wuhan First Hospital,Wuhan,Hubei,China[21]Wuhan Fourth Hospital,Wuhan,Hubei,China[22]Wuhan Sixth Hospital,Wuhan,Hubei,China[23]Xiangya Second Hospital of Central South University,Changsha,Hunan,China[24]Yueyang Central Hospital,Yueyang,Hunan,China[25]Yueyang People''s Hospital,Yueyang,Hunan,China[26]Huai''an First People''s Hospital,Huai''an,Jiangsu,China[27]Suzhou Municipal Hospital,Suzhou,Jiangsu,China[28]Xuzhou Central Hospital,Xuzhou,Jiangsu,China[29]Ganzhou People''s Hospital,Ganzhou,Jiangxi,China[30]The First Affiliated Hospital of Gannan Medical College,Ganzhou,Jiangxi,China[31]Pingxiang People''s Hospital,Pingxiang,Jiangxi,China[32]Tonghua Central Hospital,Tonghua,Jilin,China[33]The Second Hospital of Shanxi Medical University,Taiyuan,Shanxi,China[34]Shanxi Provincial People''s Hospital,Xi''an,Shanxi,China[35]West China Hospital of Sichuan University,Chengdu,Sichuan,China[36]Nanchong Central Hospital,Nanchong,Sichuan,China[37]Suining Central Hospital,Suining,Sichuan,China[38]Tianjin Medical University General Hospital,Tianjin,Tianjin,China[39]The Second Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China[40]Li Huili Hospital of Ningbo Medical Center,Ningbo,Zhejiang,China[41]Quzhou People''s Hospital,Quzhou,Zhejiang,China[42]Wenzhou Medical University Affiliated First Hospital,Wenzhou,Zhejiang,China
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/sustained-release indapamide (240 mg/1.5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with Allisartan Isoproxil (240 mg).
